Amphastar Pharmaceuticals (AMPH) Current Assets (2013 - 2026)

Amphastar Pharmaceuticals' Current Assets history runs 14 years deep, the most recent figure standing at $633.7 million for Q1 2026.

• On a quarterly basis, Current Assets rose 7.78% year-over-year to $633.7 million in Q1 2026; TTM through Mar 2026 was $633.7 million, a 7.78% increase from a year earlier, with the FY2025 full-year figure at $636.0 million, up 19.09% from the prior year.
• Current Assets was little changed at $633.7 million in Q1 2026 per AMPH's latest filing, from $636.0 million in the prior quarter.
• Across five years, Current Assets topped out at $639.5 million in Q3 2025 and bottomed at $364.4 million in Q1 2022.
• The 5-year median for Current Assets is $534.1 million (2024), against an average of $501.4 million.
• Across the five-year window, Current Assets soared 41.33% in 2023 and grew 0.54% in 2024, its largest moves.
• Year by year, Current Assets stood at $378.3 million in 2022, then rose by 29.41% to $489.6 million in 2023, then gained by 9.08% to $534.1 million in 2024, then climbed by 19.09% to $636.0 million in 2025, then fell by 0.37% to $633.7 million in 2026.
• Per Business Quant, the three latest AMPH Current Assets figures stand at $633.7 million (Q1 2026), $636.0 million (Q4 2025), and $639.5 million (Q3 2025).